{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:05:20Z","timestamp":1792292720022,"version":"4.4.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T00:00:00Z","timestamp":1581292800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T00:00:00Z","timestamp":1581292800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>In resource-limited settings, multi-experienced HIV infected patients are often prescribed raltegravir for salvage therapy. Patients failing raltegravir-containing regimens require other drugs including other integrase inhibitors. In this context, real-life data about the resistance and cross-resistance pathways between integrase inhibitors is limited. The aim of this study was to investigate integrase resistance pathways in a cohort of Mexican multi-experienced patients failing of a raltegravir-containing salvage regimen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Twenty-five plasma samples from subjects failing antiretroviral regimens which included raltegravir were obtained from various healthcare centres from 2009 to 2017 in Mexico. Antiretroviral history and demographics were collected. Samples were processed for integrase resistance genotyping testing by sequencing. The viral sequences were analysed with the Stanford HIV drug resistance database algorithm. Data was analysed with SPSS Statistics software.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We found a mean viral load of 4.17\u00a0log<jats:sup>10<\/jats:sup>\u00a0c\/mL (SD 1.11) at the time of virologic failure. Forty-eight percent of the samples were raltegravir resistant. The Y143R\/H\/C substitutions were the most prevalent, followed by the N155H, and both Q148H\/K and G140S\/A in the same proportion. The Q148\u2009+\u2009G140 combination was found in (12%) of the samples. Cross-resistance to elvitegravir was found in 83.3% and in 18.2% for both dolutegravir and bictegravir. Thirteen samples (52%) were susceptible to the four integrase strand-transfer inhibitors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our findings suggest a high occurrence of resistance and cross-resistance to other integrase inhibitors among multi-experienced subjects failing raltegravir. We found a modestly lower proportion of cross-resistance to dolutegravir than data from clinical trials. Likely this drug could be used for salvage therapy. Explanations for the absence of mutations in half of the samples, other than reduced adherence, should be further investigated. Close surveillance is needed.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12981-020-0262-y","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T18:03:10Z","timestamp":1581357790000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study"],"prefix":"10.1186","volume":"17","author":[{"given":"Aurelio","family":"Orta-Resendiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto A.","family":"Rodriguez-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis A.","family":"Angulo-Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Hernandez-Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis E.","family":"Soto-Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,10]]},"reference":[{"key":"262_CR1","doi-asserted-by":"publisher","first-page":"e97482","DOI":"10.1371\/journal.pone.0097482","volume":"9","author":"FJ Lee","year":"2014","unstructured":"Lee FJ, Amin J, Carr A. Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144\u00a0weeks\u2019 follow-up. PLoS ONE. 2014;9:e97482. https:\/\/doi.org\/10.1371\/journal.pone.0097482.","journal-title":"PLoS ONE"},{"key":"262_CR2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(03)14229-8","volume":"362","author":"G Ch\u00eane","year":"2003","unstructured":"Ch\u00eane G, Sterne JAC, May M, Costagliola D, Ledergerber B, Phillips AN, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet. 2003;362:679\u201386.","journal-title":"Lancet"},{"key":"262_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jiac.2016.10.002","volume":"23","author":"K Yoshimura","year":"2017","unstructured":"Yoshimura K. Current status of HIV\/AIDS in the ART era. J Infect Chemother. 2017;23:12\u20136. https:\/\/doi.org\/10.1016\/j.jiac.2016.10.002.","journal-title":"J Infect Chemother."},{"key":"262_CR4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506816","author":"JD Lundgren","year":"2015","unstructured":"INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015. https:\/\/doi.org\/10.1056\/NEJMoa1506816.","journal-title":"N Engl J Med."},{"key":"262_CR5","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2165\/11633630-000000000-00000","volume":"72","author":"MW Tang","year":"2012","unstructured":"Tang MW, Shafer RW. HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs. 2012;72:e1\u201325. https:\/\/doi.org\/10.2165\/11633630-000000000-00000.","journal-title":"Drugs."},{"key":"262_CR6","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1093\/jac\/dkp310","volume":"64","author":"M Wirden","year":"2009","unstructured":"Wirden M, Simon A, Schneider L, Tubiana R, Malet I, Ait-Mohand H, et al. Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug. J Antimicrob Chemother. 2009;64:1087\u201390. https:\/\/doi.org\/10.1093\/jac\/dkp310.","journal-title":"J Antimicrob Chemother"},{"key":"262_CR7","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.meegid.2016.08.031","volume":"46","author":"DS Clutter","year":"2016","unstructured":"Clutter DS, Jordan MR, Bertagnolio S, Shafer RW. HIV-1 drug resistance and resistance testing. Infect Genet Evol. 2016;46:292\u2013307. https:\/\/doi.org\/10.1016\/j.meegid.2016.08.031.","journal-title":"Infect Genet Evol."},{"key":"262_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3109\/07853890.2014.883169","volume":"46","author":"T Mespl\u00e8de","year":"2014","unstructured":"Mespl\u00e8de T, Quashie PK, Zanichelli V, Wainberg MA. Integrase strand transfer inhibitors in the management of HIV-positive individuals. Ann Med. 2014;46:123\u20139. https:\/\/doi.org\/10.3109\/07853890.2014.883169.","journal-title":"Ann Med"},{"key":"262_CR9","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.3390\/v7072790","volume":"7","author":"T Mespl\u00e8de","year":"2015","unstructured":"Mespl\u00e8de T, Wainberg MA. Resistance against integrase strand transfer inhibitors and relevance to HIV persistence. Viruses. 2015;7:3703\u201318. https:\/\/doi.org\/10.3390\/v7072790.","journal-title":"Viruses."},{"key":"262_CR10","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1093\/jac\/dkv197","volume":"70","author":"I Malet","year":"2015","unstructured":"Malet I, Thierry E, Wirden M, Lebourgeois S, Subra F, Katlama C, et al. Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance. J Antimicrob Chemother. 2015;70:2870\u201380. https:\/\/doi.org\/10.1093\/jac\/dkv197.","journal-title":"J Antimicrob Chemother"},{"key":"262_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.antiviral.2008.06.012","volume":"80","author":"M Kobayashi","year":"2008","unstructured":"Kobayashi M, Nakahara K, Seki T, Miki S, Kawauchi S, Suyama A, et al. Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. Antiviral Res. 2008;80:213\u201322. https:\/\/doi.org\/10.1016\/j.antiviral.2008.06.012.","journal-title":"Antiviral Res"},{"key":"262_CR12","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/j.1468-1293.2008.00628.x","volume":"9","author":"C Charpentier","year":"2008","unstructured":"Charpentier C, Karmochkine M, Laureillard D, Tisserand P, B\u00e9lec L, Weiss L, et al. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy. HIV Med. 2008;9:765\u201370. https:\/\/doi.org\/10.1111\/j.1468-1293.2008.00628.x.","journal-title":"HIV Med."},{"key":"262_CR13","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1128\/AAC.02096-15","volume":"60","author":"KN Andreatta","year":"2016","unstructured":"Andreatta KN, Miller MD, White KL. Drug Susceptibility and viral fitness of HIV-1 with integrase strand transfer inhibitor resistance substitution Q148R or N155H in combination with nucleoside\/nucleotide reverse transcriptase inhibitor resistance substitutions. Antimicrob Agents Chemother. 2016;60:757\u201365. https:\/\/doi.org\/10.1128\/AAC.02096-15.","journal-title":"Antimicrob Agents Chemother"},{"key":"262_CR14","doi-asserted-by":"publisher","first-page":"e106887","DOI":"10.1371\/journal.pone.0106887","volume":"9","author":"C Cesar","year":"2014","unstructured":"Cesar C, Shepherd BE, Jenkins CA, Ghidinelli M, Castro JL, Veloso VG, et al. Use of third line antiretroviral therapy in Latin America. PLoS ONE. 2014;9:e106887. https:\/\/doi.org\/10.1371\/journal.pone.0106887.","journal-title":"PLoS ONE"},{"key":"262_CR15","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/infdis\/jiu051","volume":"210","author":"A Castagna","year":"2014","unstructured":"Castagna A, Maggiolo F, Penco G, Wright D, Mills A, Grossberg R, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and\/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 2014;210:354\u201362. https:\/\/doi.org\/10.1093\/infdis\/jiu051.","journal-title":"J Infect Dis"},{"issue":"Suppl 2","key":"262_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/135965350801302S03","volume":"13","author":"DE Bennett","year":"2008","unstructured":"Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health Organization\u2019s global strategy for prevention and assessment of HIV drug resistance. Antivir Ther (Lond). 2008;13(Suppl 2):1\u201313.","journal-title":"Antivir Ther (Lond)."},{"key":"262_CR17","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1016\/S2352-3018(14)70021-9","volume":"1","author":"AN Phillips","year":"2014","unstructured":"Phillips AN, Cambiano V, Miners A, Revill P, Pillay D, Lundgren JD, et al. Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis. Lancet HIV. 2014;1:e85\u201393. https:\/\/doi.org\/10.1016\/S2352-3018(14)70021-9.","journal-title":"Lancet HIV."},{"key":"262_CR18","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0140-6736(12)60821-6","volume":"380","author":"C Beyrer","year":"2012","unstructured":"Beyrer C, Baral SD, van Griensven F, Goodreau SM, Chariyalertsak S, Wirtz AL, et al. Global epidemiology of HIV infection in men who have sex with men. Lancet. 2012;380:367\u201377. https:\/\/doi.org\/10.1016\/S0140-6736(12)60821-6.","journal-title":"Lancet"},{"key":"262_CR19","doi-asserted-by":"publisher","first-page":"e0158560","DOI":"10.1371\/journal.pone.0158560","volume":"11","author":"S Avila-Rios","year":"2016","unstructured":"Avila-Rios S, Sued O, Rhee S-Y, Shafer RW, Reyes-Teran G, Ravasi G. Surveillance of HIV transmitted drug resistance in Latin America and the Caribbean: a systematic review and meta-analysis. PLoS ONE. 2016;11:e0158560. https:\/\/doi.org\/10.1371\/journal.pone.0158560.","journal-title":"PLoS ONE"},{"key":"262_CR20","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1086\/650002","volume":"50","author":"RT Steigbigel","year":"2010","unstructured":"Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, et al. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials. Clin Infect Dis. 2010;50:605\u201312. https:\/\/doi.org\/10.1086\/650002.","journal-title":"Clin Infect Dis"},{"key":"262_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku439","author":"J de Souza Cavalcanti","year":"2015","unstructured":"de Souza Cavalcanti J, de Ferreira JL, de Guimar\u00e3es PM, Vidal JE, de Brigido LF. High frequency of dolutegravir resistance in patients failing a raltegravir-containing salvage regimen. J Antimicrob Chemother. 2015. https:\/\/doi.org\/10.1093\/jac\/dku439.","journal-title":"J Antimicrob Chemother."},{"key":"262_CR22","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1093\/nar\/gkn1050","volume":"37","author":"O Delelis","year":"2009","unstructured":"Delelis O, Malet I, Na L, Tchertanov L, Calvez V, Marcelin A-G, et al. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res. 2009;37:1193\u2013201. https:\/\/doi.org\/10.1093\/nar\/gkn1050.","journal-title":"Nucleic Acids Res"},{"key":"262_CR23","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.antiviral.2011.03.178","volume":"90","author":"C Garrido","year":"2011","unstructured":"Garrido C, Soriano V, Geretti AM, Zahonero N, Garcia S, Booth C, et al. Resistance associated mutations to dolutegravir (S\/GSK1349572) in HIV-infected patients\u2014impact of HIV subtypes and prior raltegravir experience. Antiviral Res. 2011;90:164\u20137. https:\/\/doi.org\/10.1016\/j.antiviral.2011.03.178.","journal-title":"Antiviral Res"},{"key":"262_CR24","doi-asserted-by":"publisher","first-page":"E428","DOI":"10.1111\/j.1469-0691.2012.03917.x","volume":"18","author":"F Saladini","year":"2012","unstructured":"Saladini F, Meini G, Bianco C, Monno L, Punzi G, Pecorari M, et al. Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir na\u00efve and pretreated patients. Clin Microbiol Infect. 2012;18:E428\u201330. https:\/\/doi.org\/10.1111\/j.1469-0691.2012.03917.x.","journal-title":"Clin Microbiol Infect"},{"key":"262_CR25","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/jac\/dkr152","volume":"66","author":"I Malet","year":"2011","unstructured":"Malet I, Wirden M, Fourati S, Armenia D, Masquelier B, Fabeni L, et al. Prevalence of resistance mutations related to integrase inhibitor S\/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients. J Antimicrob Chemother. 2011;66:1481\u20133. https:\/\/doi.org\/10.1093\/jac\/dkr152.","journal-title":"J Antimicrob Chemother"},{"key":"262_CR26","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1093\/jac\/dkw109","volume":"71","author":"K Anstett","year":"2016","unstructured":"Anstett K, Cutillas V, Fusco R, Mespl\u00e8de T, Wainberg MA. Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity. J Antimicrob Chemother. 2016;71:2083\u20138. https:\/\/doi.org\/10.1093\/jac\/dkw109.","journal-title":"J Antimicrob Chemother"},{"key":"262_CR27","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/jac\/dkp182","volume":"64","author":"J Ghosn","year":"2009","unstructured":"Ghosn J, Mazet A-A, Avettand-Fenoel V, Peytavin G, Wirden M, Delfraissy J-F, et al. Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen. J Antimicrob Chemother. 2009;64:433\u20134. https:\/\/doi.org\/10.1093\/jac\/dkp182.","journal-title":"J Antimicrob Chemother"},{"key":"262_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/v10010041","author":"C Charpentier","year":"2018","unstructured":"Charpentier C, Descamps D. Resistance to HIV integrase inhibitors: about R263K and E157Q mutations. Viruses. 2018. https:\/\/doi.org\/10.3390\/v10010041.","journal-title":"Viruses."}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-020-0262-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12981-020-0262-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-020-0262-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T05:32:08Z","timestamp":1665811928000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-020-0262-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,10]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["262"],"URL":"https:\/\/doi.org\/10.1186\/s12981-020-0262-y","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,10]]},"assertion":[{"value":"3 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the research and ethics boards of the Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n. All experiments were performed in compliance with relevant laws, institutional guidelines and by the ethical standards of the Declaration of Helsinki. Being a retrospective study, based on non-identifiable archived data, informed consent was not requested.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}